Retina
US Ophthalmic Review is associated with vision impairment, and once traction is released, pseudocysts generally resolve with improvement in vision. 5 Both VMA and VMT can be subclassified into either focal (≤1,500 µm) or broad (>1,500 µm) adhesions based on attachment size (see Table 1 ).
Focal areas of vitreous attachment with traction tend to distort the foveal surface, whereas broad areas of attachment with traction can cause generalized thickening of the macula, vascular leakage on fluorescein angiography, macular schisis, and cystoid macular edema. 2 Excessive traction on the inner retina may also result in the development of a full-thickness macular hole (FTMH), defined as an anatomic defect in the fovea featuring interruption of all neural retinal layers from the internal limiting membrane (ILM) to the RPE. 2, 3 FTMH can have either persistent VMT or complete release of the vitreous. Using an OCT-based system, the presence of continued VMT and measurements of minimum hole width (aperture size) become important as the aperture size of the FTMH and the presence of residual VMT can help determine appropriate treatment options. 3 In a small number of cases, VMT may resolve spontaneously, with multiple factors contributing to the likelihood of spontaneous resolution, including the tenacity of the adhesion between the vitreous gel and macula, and presence of an epiretinal membrane (ERM). 4, [6] [7] [8] Consequently, spontaneous resolution is hard to predict, and watchful waiting has been the standard of care for early or mild cases, with pars plana vitrectomy (PPV) usually reserved for more chronic or severe cases. 9 Until the approval of ocriplasmin in 2012, vitrectomy and watchful waiting were the only management strategies for patients with tractional diseases of the VMI. Therefore, understanding the appropriate clinical use as well as the limitations of ocriplasmin is crucial, as it becomes an additional tool for the treatment of symptomatic VMA/VMT.
Financial considerations are definitely a factor in the choice of treatment strategy. The cost of the drug should be weighed against the benefits and needs to be discussed thoroughly with the patients along with the clinical aspects of disease management.
Ocriplasmin Efficacy
Ocriplasmin is a truncated form of plasmin that enzymatically cleaves structural proteins, including laminin and fibronectin, at the VMI. Results of preclinical and clinical studies have suggested that ocriplasmin can induce vitreous liquefaction and separation from the retina. [10] [11] [12] In its initial phase of development, ocriplasmin was evaluated as an adjunct to vitrectomy to assess its effectiveness in the achievement of complete PVD. A preliminary clinical study assessed intravitreal ocriplasmin at varying doses administered either 1-2 hours, 24 hours, or 7 days before planned PPV for VMT. 12 Increasing the duration of observation after exposure to ocriplasmin was associated with a progressive increase in the incidence of complete PVD achievement. Subsequently, two phase III clinical trials with similar designs were conducted to assess the efficacy and safety of a single intravitreal injection of ocriplasmin in patients with VMT with or without associated FTMH (400 μm or less). 13 The percentage of eyes achieving the primary endpoint, which was resolution of VMA at day 28, was significantly greater with ocriplasmin than with vehicle: 26.5 % versus 10.1 % (p<0.001), respectively. 13 In addition, a significantly higher proportion of patients achieved the secondary endpoints compared with those receiving the vehicle, including: (a) 13. Table 2 ).
15-17
Regarding visual outcomes, recent publications have reported modest gains, and highlight the need for longer-term follow-up studies. Kim et al. reported modest VA gains, with eight out of 19 (41 %) patients treated gaining 2 ETDRS lines or fewer, and another 41 % with no change in baseline vision. 15 Singh et al. reported that although there was a trend of improved VA in the group of patients who achieved VMA release, this was not statistically different from the patients without VMA release. 17 The authors also note that the use of standard Snellen acuity, rather than protocol VA, and the short follow-up period might have blunted the VA outcomes. 
Ocriplasmin Safety
In the pivotal phase III ocriplasmin clinical trials, the proportion of patients who had any ocular adverse event in the study eye was 68.4 % in the ocriplasmin group and 53.5 % in the vehicle group (p<0.001) (see Table   3 ). Interestingly, this difference was driven primarily by adverse events known to be associated with vitreous detachment, as the most common ocular adverse event in the study eye was vitreous floaters, reported by 16.8 % of patients in the ocriplasmin group and 7.5 % of those in the vehicle group. 13 Retinal tears or detachments were diagnosed in 1.9 % of the patients given ocriplasmin compared with 4.3 % of those given vehicle.
Most retinal breaks in both groups occurred during or after vitrectomy; two (0.4 %) retinal detachments in the ocriplasmin group and one (0.5 %)
retinal tear in the vehicle group occurred prior to any vitrectomy.
Most suspected treatment-related ocular adverse events were not serious, mild in severity, and occurred within 7 days after injection.
Of the 465 patients treated in the phase III studies, 36 patients (7.7 %) reported an acute reduction in VA. Three patients (0.65 %) experienced a transient significant (≤20/200) reduction in VA. Time-to-onset was less than 7 days, and median time to resolution was 14 days. There were 36 patients with acute vision loss, and 83 % resolved by the 6-month study endpoint. Vision loss persisted in six patients (1.3 % of total patients):
five of these six patients had complications related to vitrectomy (n=4)
or needed vitrectomy (n=1); one of the six patients had vision loss for unknown reasons despite VMA resolution and anatomic improvement.
Overall, most cases were transient, as by the end of the 6-month study reduced VA was reported in approximately 1 % of patients in both the ocriplasmin-and vehicle-treated groups (see Figure 1) . Disruption of the ellipsoid zone on OCT was also noted at day 1, with improvement reported by 2 months. In this patient, ERG abnormalities were observed, with rods (scotopic vision) affected more than cones (photopic vision); these abnormalities persisted to 4 months. The authors conclude that further work is necessary to identify potential effects of ocriplasmin on photoreceptors, and to identify those patients who may be at risk of these adverse events.
Periodic reporting plays a major role in the safety assessment of a drug, as spontaneous reporting allows health authorities to gather safety information on newly available treatment options. Considered one of the most important aggregate reports worldwide, the Periodic Benefit-Risk Evaluation Report (PBRER) is submitted to drug regulatory authorities in Europe, the US, and Japan, as well as in other countries. 20 It is updated biannually and contains the results from an ongoing collection of postmarketing surveillance data. The focus of the PBRER is on the benefit-risk profile of the drug, which includes a review of relevant safety information compiled for a drug product in market and throughout its development. The safety reports consist of preclinical, clinical trial, and 
Overall Conclusions
Ocriplasmin is a novel, efficacious treatment option for patients with VMA, as demonstrated by the results from the phase III trials, 13 as well as recently published reports. [15] [16] [17] Efficacy data from ocriplasmin use in a clinical setting have supported the subanalysis of phase III data, which demonstrated that certain baseline ocular characteristics, primarily focal VMA, and absence of ERM, are predictive of VMA resolution and are important for optimal patient selection.
Safety findings show that the overall percentage of patients experiencing adverse events during the clinical trial program was low in ocriplasmintreated patients. Ocriplasmin was well-tolerated and most treatmentrelated ocular adverse events were not serious, were mild in severity, and occurred within 7 days post injection. 13, 21 Postmarketing surveillance data corroborate findings from the phase III trials, and provide additional insights into the characterization of the safety profile of ocriplasmin.
Further understanding is needed on some of the observations that had not been reported in the phase III trials, such as ellipsoid zone changes.
Identifying which patients are more likely to develop particular adverse events is important; however, as of yet the adverse events appear to be unpredictable. Interestingly, ellipsoid zone changes may be a positive predictor of response, as it was reported to occur more frequently in patients who had VMA release. 17 Further studies are needed to clarify the mechanisms involved.
A number of phase IIIb/IV studies are currently ongoing to address some Based on the available data, ocriplasmin can be considered a safe treatment option, especially considering its mechanism of action (enzymatic cleavage of structural proteins) as well as the fact that it is commonly used as an alternative to surgical vitrectomy, which has its own set of side effects.
In fact, ocriplasmin could be viewed as a gentler form of vitrectomy, as it pharmacologically induces an increase in traction, accelerating the process that leads to VMA release. In addition, the frequency of certain types of adverse events observed following treatment with ocriplasmin is consistent with what has been reported for vitrectomy. A recently published systematic review of the literature to determine the safety and efficacy of PPV for vitreomacular syndrome identified focal, petechial, spontaneously resolving retinal hemorrhage, and peripheral retinal breaks as the most frequent intraoperative complications, with 6 % and 2 % of eyes affected, respectively. For postoperative complications, the events with the highest percentage of eyes affected were cataract (35 %), cataract surgery (11 %), epimacular/ERM (6 %), and retinal detachment (5 %). 22 The authors also noted that approximately one-third of eyes treated with PPV for VMT gained 2 Snellen lines, and suggested that these gains may be less than anticipated. As additional data on ocriplasmin efficacy is being generated, a closer evaluation of the outcomes and adverse events associated with vitrectomy should also be considered.
Overall, both the clinical trial data and the emerging real world experience
show that ocriplasmin appears to be an effective and safe treatment option, and provides a new addition to our armamentarium in the management of vitreo-retinal interface disorders. n
